Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELMI: Empagliflozin + Linagliptin vs Metformin + Insulin Glargine in T2DM
NCT02752113Phase 3Completed
- Sponsor
- Institut für Pharmakologie und Präventive Medizin
- Start
- Apr 2016
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of empagliflozin, linagliptin in type 2 diabetes mellitus (T2DM), sponsored by Institut für Pharmakologie und Präventive Medizin. Started Apr 2016; status: completed.
02
Drugs
empagliflozinlinagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02752113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02752113.